-
Mashup Score: 2
AstraZeneca proudly partners with Hockey Fights CancerTM. Join the Get Body Checked Against Cancer campaign for simple steps in facing cancer with courage.
Source: www.getbodychecked.comCategories: General Medicine News, PayerTweet
-
Mashup Score: 4New York Rangers captain Jacob Trouba may be the most interesting man in hockey, on and off the ice - 4 day(s) ago
New York Rangers captain Jacob Trouba might be the most interesting man in the NHL. Trouba asked for a trade to an American team to make sure his fiancée could pursue her medical career.
Source: apnews.comCategories: General Medicine News, PayerTweet
-
Mashup Score: 4
AstraZeneca proudly partners with Hockey Fights CancerTM. Join the Get Body Checked Against Cancer campaign for simple steps in facing cancer with courage.
Source: www.getbodychecked.comCategories: General Medicine News, PayerTweet
-
Mashup Score: 12The Crucial Role of Genetic Testing in Amyloidosis - 12 day(s) ago
What is Hereditary ATTR (hATTR)? Hereditary transthyretin-mediated amyloidosis (hATTR) is an inherited genetic condition affecting a protein called transthyretin (TTR). 1 A variant in the TTR gene causes the protein to become abnormally shaped and misfolded. This misfolded TTR forms amyloid fibrils which can build up and deposit in the nerves, digestive system, heart and other tissues and organs, causing a variety of symptoms such as numbness, pain or tingling in the hands and feet, shortness of breath,
Source: www.astrazeneca-us.comCategories: General Medicine News, PayerTweet
-
Mashup Score: 3Cardiovascular Disease | AstraZeneca - 22 day(s) ago
Cardiovascular disease is a leading cause of death worldwide. Learn more about our ambition to eliminate risk factors and stop disease progression.
Source: www.astrazeneca.comCategories: General Medicine News, PayerTweet
-
Mashup Score: 6
AstraZeneca and Daiichi Sankyo’s ENHERTU ® (fam-trastuzumab deruxtecan-nxki) has been approved in the US for the treatment of adult patients with unresectable or metastatic HER2-positive (IHC 3+) solid tumors who have received prior systemic treatment and have no satisfactory alternative treatment options. This indication is approved under accelerated approval based on objective response rate (ORR) and duration of response (DoR). Continued approval for this indication may be contingent upon verification
Source: www.astrazeneca-us.comCategories: General Medicine News, PayerTweet
-
Mashup Score: 9
Positive high-level results of the ADRIATIC Phase III trial showed AstraZeneca’s IMFINZI® (durvalumab) demonstrated a statistically significant and clinically meaningful improvement in the dual primary endpoints of overall survival (OS) and progression-free survival (PFS) in patients with limited-stage small cell lung cancer (LS-SCLC) who had not progressed following concurrent chemoradiotherapy (cCRT) compared to placebo after cCRT. Small cell lung cancer (SCLC) is a highly aggressive form of lung
Source: www.astrazeneca-us.comCategories: General Medicine News, PayerTweet
-
Mashup Score: 6
AstraZeneca and Daiichi Sankyo’s Biologics License Application (BLA) for datopotamab deruxtecan (Dato-DXd) has been accepted in the US for the treatment of adult patients with unresectable or metastatic hormone receptor (HR)-positive, HER2-negative (IHC 0, IHC 1+ or IHC 2+/ISH-) breast cancer who have received prior systemic therapy for unresectable or metastatic disease. The Prescription Drug User Fee Act date, the US Food and Drug Administration (FDA) action date for its regulatory decision, is during
Source: www.astrazeneca-us.comCategories: General Medicine News, PayerTweet
-
Mashup Score: 2TIME logo - 27 day(s) ago
This is paid content on behalf of our sponsor. TIME editorial staff was not involved in its creation or production.
Source: partners.time.comCategories: General Medicine News, PayerTweet
-
Mashup Score: 3
Latest analysis of the results from the DUO-E Phase III trial showed IMFINZI ® (durvalumab) plus platinum-based chemotherapy followed by IMFINZI plus LYNPARZA ® (olaparib) (LYNPARZA and IMFINZI arm) demonstrated an improvement in multiple key secondary efficacy endpoints, particularly in patients with mismatch repair proficient (pMMR) advanced or recurrent endometrial cancer compared to chemotherapy alone. These results will be presented today in a late-breaking session at the 2024 Society of Gynecologic
Source: www.astrazeneca-us.comCategories: General Medicine News, PayerTweet
Chie Chie Yard, a former Japanese National Team hockey player and current NHL employee, sheds light on how early detection and routine screenings were key in fighting breast cancer. Ask your doctor about cancer screenings right for you and learn more at https://t.co/WaS1klXiKp https://t.co/KvqSYo32Nh